WALTHAM, MA • 2019-07-23

BostonGene Announces Partnership with National Institutes of Health

5 min to read

Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment
Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment

WALTHAM, MA – July 23, 2019 – BostonGene Corporation (BostonGene), a biomedical software company, today announced its partnership with the National Institutes of Health (NIH) including the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID).

BostonGene’s solution will provide NCI and NIAID with an interpretation and visualization of a patient's next-generation sequencing (NGS) information within the landscape of a patient’s genetic and genomic data at a desired level of complexity. The solution will identify all significant somatic alterations, evaluation of protein expression, estimation of tumor heterogeneity, prediction of neoantigens, tumor clonality, hereditary predisposition, viral infestation and pharmacogenomics among other molecular features. BostonGene generates a visually-appealing and self-explanatory tumor schematics, called MF Portrait™, depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

“Immuno- and targeted therapies are the most promising and rapidly developing treatments for cancer. BostonGene is thrilled to be partnering with NIH to provide sophisticated data analytics to produce viable treatment options personalized for each patient. Our mission is to treat the patient, not treat the diagnosis,” said Andrew Feinberg, President and CEO of BostonGene.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene offers customized client solutions using a multi-omic approach prioritized for real-world impact, optimizing standard-of-care therapies, accelerating research and delivering cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth analysis of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies and recommended treatments. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director